Pembrolizumab + Olaparib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma, Ocular Melanoma
Trial Timeline
Oct 11, 2022 → Dec 1, 2027
NCT ID
NCT05524935About Pembrolizumab + Olaparib
Pembrolizumab + Olaparib is a phase 2 stage product being developed by Merck for Uveal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05524935. Target conditions include Uveal Melanoma, Ocular Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05379972 | Phase 2 | Active |
| NCT05524935 | Phase 2 | Recruiting |
| NCT05156268 | Phase 2 | Active |
| NCT04666740 | Phase 2 | Active |
| NCT04483544 | Phase 2 | Terminated |
| NCT03025035 | Phase 2 | Completed |
Competing Products
20 competing products in Uveal Melanoma